Phage‐Antibiotic Combinations for Pseudomonas : Successes in the Clinic and In Vitro Tenuously Connected
Microbial Biotechnology · 2025
DOI: 10.1111/1751-7915.70193 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Rabia Fatima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pseudomonas aeruginosa, Pseudomonas Infections, Phage Therapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Farncombe Family Chair in Phage Biology.
Abstract (Originalsprache)
Antimicrobial resistance challenges researchers to innovate strategies to enhance the effectiveness of our existing antibiotics. Bacteriophage (phage, bacterial virus)‐antibiotic combinations present a promising synergistic approach, particularly for drug‐resistant infections such as those caused by Pseudomonas aeruginosa. This approach offers many advantages: enhanced bacterial killing (both planktonic and biofilm), eliminating persister cells, re‐sensitization to drugs, and inhibiting resistance spread by targeting plasmids encoding resistant genes. Interestingly, even phages traditionally excluded from therapy – those capable of entering dormancy in the bacterial host – exhibit unique, potent synergy with antibiotics. Despite these clear in vitro benefits and the comparatively strong performance of phage antibiotic combinations in the clinic, translating in vitro efficacy to patient outcomes remain challenging. The lack of standardized metrics for measuring phage‐antibiotic interaction complicates cross‐study comparisons. In many instances, it is also difficult to translate these in vitro findings to clinically relevant metrics – for example, increased progeny size in vitro is unlikely to contribute meaningfully to treatment success. Addressing these gaps will allow us to fully harness the potential of phage‐antibiotic combinations and bridge the disconnect between in vitro results and clinical success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
- Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Alexander P Hynes
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Farncombe Family Chair in Phage Biology
Zitieren
APA
Fatima, R., & Hynes, A. P. (2025). Phage‐Antibiotic Combinations for Pseudomonas : Successes in the Clinic and In Vitro Tenuously Connected. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70193
Vancouver
Fatima R, Hynes AP. Phage‐Antibiotic Combinations for Pseudomonas : Successes in the Clinic and In Vitro Tenuously Connected. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70193
BibTeX
@article{Fatima2025,
author = {Fatima, Rabia and Hynes, Alexander P},
title = {Phage‐Antibiotic Combinations for Pseudomonas : Successes in the Clinic and In Vitro Tenuously Connected},
journal = {Microbial Biotechnology},
year = {2025},
doi = {10.1111/1751-7915.70193}
}
EUVIMED